More than a dozen studies of Ocrevus for multiple sclerosis presented at ECTRIMS.
These data include abstracts highlighting new longer-term efficacy and safety for Ocrevus as well as ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS.
Ocrevus data also shows sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS). In addition, long-term safety analysis of all clinical trials will reinforce the consistently favorable benefit-risk profile of Ocrevus. A subgroup analysis of three studies (SaROD, CHORDS and ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2-hour Ocrevus infusion will be presented.
Abstracts include: "Sustained Reduction in 48-week Confirmed Disability Progression in Patients with PPMS Treated with Ocrelizumab in the ORATORIO OLE: 8-Year Follow-up", "Long-term Reduction of Relapse Rate and Confirmed Disability Progression After 7.5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis in the OPERA OLE" and "Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins